Furthermore, ibrutinib-treated CLL patients showed progressive downregulation of NOTCH1 activity during therapy, which was restored at relapse and remained activated in ibrutinib-resistant disease. The gene discussed is NOTCH1; the disease is B-cell chronic lymphocytic leukemia.